Investor Presentation First Nine Months of 2022
17
Investor presentation
First nine months of 2022
Strategic aspirations 2025
sustainability
Purpose and
(ESG)
•
Progress towards zero environmental impact
Being respected for adding value to society
Being recognised as a sustainable employer
Innovation and
therapeutic focus
Further raise the innovation-bar for diabetes treatment
Develop a leading portfolio of superior treatment
solutions for obesity
Strengthen and progress the Rare disease pipeline
•
Establish presence in Other serious chronic diseases
focusing on CVD, NASH and CKD
ピ
Commercial
execution
Strengthen Diabetes leadership - aim at global value
market share of more than 1/3
More than 25 billion DKK in Obesity sales by 2025
Secure a sustained growth outlook for Rare disease
11
Financials
•
Deliver solid sales and operating profit growth
•
Deliver 6-10% sales growth in IO
•
• Transform 70% of sales in the US¹
Drive operational efficiencies across the value chain to
enable investments in future growth assets
• Deliver free cash flow to enable attractive capital
allocation to shareholders
1 From 2015 to 2022, 70% of sales to come from products launched from 2015. IO: International Operations; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic kidney disease.
Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth.
Novo NordiskⓇView entire presentation